Atorvastatin Prevents the Downregulation of Aquaporin-2 Receptor After Bilateral Ureteral Obstruction and Protects Renal Function in a Rat Model


Autoria(s): Danilovic, Alexandre; Lopes, Roberto Iglesias; Sanches, Talita Rojas; Massola Shimizu, Maria Heloisa; Oshiro, Fabiola M.; Andrade, Lucia; Denes, Francisco Tibor; Seguro, Antonio Carlos
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

21/10/2013

21/10/2013

2012

Resumo

OBJECTIVE To assess the effects of atorvastatin (ATORV) on renal function after bilateral ureteral obstruction (BUO), measuring inulin clearance and its effect on renal hemodynamic, filtration, and inflammatory response, as well as the expression of Aquaporin-2 (AQP2) in response to BUO and after the release of BUO. METHODS Adult Munich-Wistar male rats were subjected to BUO for 24 hours and monitored during the following 48 hours. Rats were divided into 5 groups: sham operated (n = 6); sham + ATORV (n = 6); BUO (n = 6); BUO + ATORV (10 mg/kg in drinking water started 2 days before BUO [n = 5]; and BUO + ATORV (10 mg/kg in drinking water started on the day of the release of BUO [n = 5]). We measured blood pressure (BP, mm Hg); inulin clearance (glomerular filtration rate [GFR]; mL/min/100 g); and renal blood flow (RBF, mL/min, by transient-time flowmeter). Inflammatory response was evaluated by histologic analysis of the interstitial area. AQP2 expression was evaluated by electrophoresis and immunoblotting. RESULTS Renal function was preserved by ATORV treatment, even if initiated on the day of obstruction release, as expressed by GFR, measured by inulin clearance. Relative interstitial area was decreased in both BUO + ATORV groups. Urine osmolality was improved in the ATORV-treated groups. AQP2 protein expression decreased in BUO animals and was reverted by ATORV treatment. CONCLUSION ATORV administration significantly prevented and restored impairment in GFR and renal vascular resistance. Furthermore, ATORV also improved urinary concentration by reversing the BUO-induced downregulation of AQP2. These findings have significant clinical implication in treating obstructive nephropathy. UROLOGY 80: 485.e15-485.e20, 2012. (c) 2012 Elsevier Inc.

Identificador

UROLOGY, NEW YORK, v. 80, n. 2, supl. 2, Part 3, pp. 1277-1280, AUG, 2012

0090-4295

http://www.producao.usp.br/handle/BDPI/35315

10.1016/j.urology.2012.02.021

http://dx.doi.org/10.1016/j.urology.2012.02.021

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE INC

NEW YORK

Relação

UROLOGY

Direitos

closedAccess

Copyright ELSEVIER SCIENCE INC

Palavras-Chave #ATRIAL-NATRIURETIC-PEPTIDE #WATER CHANNELS #EXPRESSION #TRANSPORTERS #NEPHROPATHY #INHIBITION #DIURESIS #FIBROSIS #FAILURE #UROLOGY & NEPHROLOGY
Tipo

article

original article

publishedVersion